WEBULL
News
IDYA
33.09
+0.79%
0.26
Is IDEAYA Biosciences (IDYA) Quietly Assembling a Focused MTAP-Deletion Oncology Franchise?
Simply Wall St · 3d ago
IDEAYA Biosciences (IDYA) Gets a Buy from Wedbush
TipRanks · 3d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 3d ago
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating
TipRanks · 4d ago
Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Lantheus (LNTH)
TipRanks · 4d ago
Ideaya Biosciences enrolls first patient in IDE892 trial
TipRanks · 4d ago
Ideaya Biosciences Enrolls The First Patient In Its Phase 1 Trial Of IDE892 for MTAP-Deleted Solid Tumors, Including Non-small Cell Lung Cancer And Pancreatic Cancer
Benzinga · 4d ago
IDEAYA Biosciences reports first patient enrolled in Phase 1 IDE892 trial for MTAP-deleted solid tumors
Reuters · 4d ago
IDEAYA BIOSCIENCES INC - TARGETS CDKN2A DEVELOPMENT CANDIDATE NOMINATION IN H2 2026 AND IND IN H1 2027
Reuters · 4d ago
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
PR Newswire · 4d ago
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Roche Holding AG (OtherRHHVF)
TipRanks · 4d ago
Weekly Report: what happened at IDYA last week (0302-0306)?
Weekly Report · 4d ago
IDEAYA Biosciences (IDYA) Valuation Check As Phase 1 IDE034 Trial Marks Key Pipeline Milestone
Simply Wall St · 6d ago
Citi opens ‘upside 90-day catalyst watch’ on Ideaya Biosciences
TipRanks · 03/06 11:41
Notable Thursday Option Activity: MDB, SOC, IDYA
NASDAQ · 03/05 21:16
Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy?
Simply Wall St · 03/03 09:29
IDEAYA Biosciences Director Jeffrey Stein Acquires Common Shares
Reuters · 03/03 00:18
Weekly Report: what happened at IDYA last week (0223-0227)?
Weekly Report · 03/02 09:05
Reported Friday, Biocytogen Announces First Patient Dosed In IDEAYA's Phase 1 Trial Of First-In-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034, Triggering $5M Milestone Payment
Benzinga · 03/02 08:05
More
Webull provides a variety of real-time IDYA stock news. You can receive the latest news about Ideaya Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).